FOERFARANDE FOER FRAMSTAELLNING AV LOKALANESTETISKT VERKANDE 2-ALKYL-2-ALKYLAMINO-2',6'-ACETOXYLIDIDER

1369259 Xylidine derivatives ASTRA PHARMACEUTICAL PRODUCTS Inc 21 Dec 1971 [22 Dec 1970 19 July 1971] 59377/71 Heading C2C Novel xylidine derivatives of the Formula I wherein R1 is ethyl, propyl, or butyl; R2 and R3 each are methyl, ethyl, propyl or butyl or R2 and R3 together is tetramethylene; the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ADAMS HERBERT JOHN FREDERICK, KRONBERG GEORGE HERBERT, TAKMAN BERTIL HERBERT
Format: Patent
Sprache:fin
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:1369259 Xylidine derivatives ASTRA PHARMACEUTICAL PRODUCTS Inc 21 Dec 1971 [22 Dec 1970 19 July 1971] 59377/71 Heading C2C Novel xylidine derivatives of the Formula I wherein R1 is ethyl, propyl, or butyl; R2 and R3 each are methyl, ethyl, propyl or butyl or R2 and R3 together is tetramethylene; the total sum of carbon atoms in R1, R2 and R3 being at least six; and pharmaceutically acceptable acid addition salts thereof are prepared by reacting the appropriate 2-alkyl-2-bromo-(or iodo)-21,61- acetoxylides with amines of the formula H-NR2R3, or with amines of the formula R2NH 2 , and reacting the thus obtained 2-alkyl- 2-alkylamino-21,61-acetozylidides, with alkylating agents. The racemic compounds thus obtained may be resolved by treatment with l- and d-tartaric acid. 2 - Alkyl - 2 - iodo - 21,61- acetoxylidides are obtained by reacting potassium iodide with the corresponding 2 - alkyl - 2 - bromo - 21,61- acetoxylidides, resulting from the reaction between the appropriate acid chloride and 2,6-xylidine. 2-Bromobutyryl chloride is obtained by reacting 2-bromobutyric acid with thionyl chloride. Pharmaceutical compositions, suitable for parenteral or topical administration, contain the above novel compounds or pharmaceutically acceptable acid addition salts thereof in association with pharmaceutically acceptable carriers. The compounds possess local anaesthetic activity.